Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder
Journal of Affective Disorders, Volume 265, Year 2020
Notification
URL copied to clipboard!
Description
Introduction: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are recommended as an integrative treatment for major depressive disorder (MDD). In 2019, the International Society for Nutritional Psychiatry Research (ISNPR) developed the first practice guidelines for n-3 PUFA treatment of MDD. To strengthen these guidelines and enhance their clinical applicability, we synthesized the evidence and clinical experiences previously obtained through the Delphi methodology. Methods: Nineteen statements covering five major domains in MDD treatment were formulated through internal meetings. Fourteen international experts were invited to participate in the web-based Delphi process that validated the statements. Likert scales were used, and consensus level was set at 7.0/10.0, with the equivocal level set at 5.1–6.9. The items with scores < 5.0 were allocated into a second round Delphi survey with inverse questions. Results: All panelists completed the survey. Sixteen statements reached consensus, and the statement “n-3 PUFAs are one of the potential adjunctive treatments for adult MDD” reached the highest agreement. “N-3 PUFAs are one of the potential monotherapies for adult MDD” instead scored lowest. Regarding “special populations,” many items, reached high consensus despite sub-optimal supportive evidence. Limitation: The panelists had a specialized interest in n-3 PUFAs; focus was placed on clinical issues rather than on biological mechanisms. Conclusions: The Delphi process helps bridge the gap between scientific evidence and clinical practice, supports certain uses of PUFA and identifies insufficiency in current evidence that merit future research. © 2020 Elsevier B.V.
Authors & Co-Authors
Mischoulon, David
United States, Boston
Massachusetts General Hospital
Sarris, Jerome
Australia, Penrith
Western Sydney University
Australia, Melbourne
University of Melbourne
Hibbeln, Joseph R.
United States, Bethesda
National Institute on Alcohol Abuse and Alcoholism Niaaa
Hamazaki, Kei
Japan, Toyama
University of Toyama
Freeman, Marlene P.
United States, Boston
Massachusetts General Hospital
Maes, Michael H.J.
Thailand, Bangkok
Chulalongkorn University
Matsuoka, Yutaka J.
Japan, Tokyo
National Cancer Center Japan
Belmaker, Robert Haim
Israel, Beer-sheva
Ben-gurion University of the Negev
Marx, Wolfgang
Australia, Geelong
Deakin University
Pariante, Carmine M.
United Kingdom, London
King's College London
Berk, Michael
Australia, Geelong
Deakin University
Australia, Melbourne
Orygen Youth Health
Jacka, Felice Nellie
Australia, Geelong
Deakin University
Su, Kuanpin
Taiwan, Taichung
China Medical University Hospital
Taiwan, Taichung
China Medical University
Statistics
Citations: 10
Authors: 13
Affiliations: 14
Identifiers
Doi:
10.1016/j.jad.2020.01.050
ISSN:
01650327
Study Design
Cross Sectional Study
Study Approach
Quantitative